Changes in the burden of lower respiratory infections in China before and after the implementation of the national centralized drug procurement policy.

Juan Hu, Yongzhong Tang, Duoduo Li, Zhenguo Liu, Wen Ouyang, Pengcheng Zhou

Abstract read

In one paragraph

Article in Infectious medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Juan HuDepartment of Infectious Diseases, The Third Xiangya Hospital of Central South University, Changsha 410013, China.

Yongzhong TangDepartment of Anesthesiology, The Third Xiangya Hospital of Central South University, Changsha 410013, China.

Duoduo LiDepartment of Infectious Diseases, The Third Xiangya Hospital of Central South University, Changsha 410013, China.

Zhenguo LiuDepartment of Infectious Diseases, The Third Xiangya Hospital of Central South University, Changsha 410013, China.

Wen OuyangDepartment of Anesthesiology, The Third Xiangya Hospital of Central South University, Changsha 410013, China.

Pengcheng ZhouDepartment of Infectious Diseases, The Third Xiangya Hospital of Central South University, Changsha 410013, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The implementation of the National Centralized Drug Procurement (NCDP) policy has had far-reaching effects. This study aims to assess the impact of the NCDP policy on the disease burden of lower respiratory infections (LRIs) in China. Methods: The age-standardized incidence rates (ASIR), age-standardized mortality rates (ASMR), and age-standardized disability-adjusted life-years rates (ASDR) from the Global Burden of Disease (GBD) 2021 database were used to describe the disease burden and compare it before (1990-2017) and after (2019-2021) the implementation of the NCDP policy. We applied interrupted time series (ITS) analysis to assess changes in the burden of LRIs before and after policy implementation, with 2018 designated as the intervention cutoff year. Results: The ITS analysis revealed a consistent declining trend in the ASIR, ASMR, and ASDR for LRIs in China from 1990 to 2021. Following the implementation of the NCDP policy in 2018, all three indicators showed a statistically significant acceleration in reduction. The ASIR decreased from 5,481.13 to 2,853.81 per 100,000 population. Following policy implementation (2019-2021), the slope of the ASIR was estimated to be -185.73, also indicating a statistically significant declining trend ( Conclusions: After the implementation of the NCDP policy, the disease burden of LRIs in China decreased, suggesting that the policy effectively reduced the disease burden on patients.

Indexed as

Disease burdenInterrupted time seriesLower respiratory infectionsNational centralized drug procurement

Identifiers

PMID42206065

DOI10.1016/j.imj.2026.100257

PMCPMC13202257

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.